Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer.
Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer.
复制标题
DOI：
10.1016/j.urolonc.2011.02.002
复制
发表时间：
2012-11
期刊：
影响因子：
--
通讯作者：
Diefenbach MA
中科院分区：
文献类型：
--
作者：
Mohamed NE;Bovbjerg DH;Montgomery GH;Hall SJ;Diefenbach MA
This study examined whether depressive symptoms before localized prostate cancer treatment predict disease specific quality of life (i.e., sexual and urinary dysfunction, sexual and urinary bother, and activity limitation due to urinary dysfunction) reported six months following treatment among newly diagnosed patients. A case series of patients recently diagnosed with localized prostate cancer (T1-2N0M0) at FCCC were eligible. Of the 1370 eligible patients, 869 (63.34%) completed questionnaires at diagnosis (baseline) and six months following treatment. Patients were treated with surgery (16.8%), brachytherapy (27.6%), or external beam radiation (55.6%). Depressive symptoms and disease specific quality of life were assessed with established measures (i.e., Center for Epidemiologic Studies Depression Scale (CES-D); sexual adjustment questionnaire (SAQ); and the American Urological Association symptom index). A fifth of the sample (19.7%) reported clinically elevated levels of depression. All aspects of disease specific QOL decreased significantly between baseline and six months following treatment. Depressive symptoms at baseline significantly predicted sexual and urinary dysfunction, related bother, and activity limitation due to urinary dysfunction at 6-month controlling for age, PSA level, Gleason score, treatment type, and relevant baseline indicators of sexual and urinary dysfunction, related bother and activity limitation (ps < .05). Depressive symptoms before prostate cancer treatment predict disease-specific quality of life after treatment. Health care providers should be sensitive to the display of depressive symptoms before treatment and consider preventative interventions including at the least, preparing patients for the changes in disease-specific QOL and related bother following prostate cancer treatment.
登录
查看更多内容
影响因子：
8.8
作者：
Helgason, A;Adolfsson, J;Dickman, P;Fredrikson, M;Arver, S;Steineck, G
通讯作者：
Steineck, G
影响因子：
6.6
作者：
Brandeis, JM;Litwin, MS;Reiter, RE
通讯作者：
Reiter, RE
影响因子：
45.3
作者：
Clark, JA;Inui, TS;Talcott, JA
通讯作者：
Talcott, JA
影响因子：
3.6
作者：
Deimling, GT;Kahana, B;Schaefer, ML
通讯作者：
Schaefer, ML
DOI：
10.1053/suro.2002.30399
发表时间：
2002-02-01
期刊：
Seminars in urologic oncology
影响因子：
--
作者：
Diefenbach, Michael A;Dorsey, Jenevie;Engstrom, Paul F
通讯作者：
Engstrom, Paul F